Scatter plot representation of ELISA values in Hashimoto's thyroiditis patients compared to healthy controls.

<p>Scatter plots for MAP3865c_125–133 (<b>A</b>) and its homologous ZnT8_178–186 (<b>B</b>) and MAP3865c_133–141 (<b>C</b>) and its homologous ZnT8_186–194 (<b>D</b>) representing the IgG antibodies distribution against these epitopes in Hashimoto's thyroiditis patients and healthy subjects. The number of serum samples in each group is indicated. Dotted lines indicate the cutoff, while bars indicate the corresponding median ± interquartile range. The percent fraction of antibody positive sera is indicated on top of each distribution, whereas AUC and <i>p</i> values are given in the top right corner.</p

Scatter plots representing the IgG antibodies distribution against MAP3865_262–275 C-terminal epitope in Hashimoto's thyroiditis patients compared to healthy controls.

<p>Data representation is the same as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0097621#pone-0097621-g001" target="_blank">Figure 1</a>.</p

Prevalence of Abs against MAP3865c epitopes falling into the region of homology comprising the polymorphic Znt8 325^th residue in 29 Type 1 Diabetes (T1D) and 30 healthy controls (HCs) Sardinian children.

<p>Sera were tested for their reactivity against plate-coated with MAP3865c_246–252 (A) MAP3865c_256–262 (B) MAP3865c_261–267 (C) and MAP3865c_281–287 (D) peptides. Data representation is the same as in Fig. 1.</p

Prevalence of Abs against homologous ZnT8 and MAP3865c transmembrane epitopes in Type 1 Diabetes (T1D), and healthy controls (HCs) Sardinian children.

<p>Sera were tested for their reactivity against plate-coated with MAP3865c_125–133(A) and its homologous ZnT8_178–186 (B); and with MAP3865c_133–141 (C) and its homologous ZnT8_186–194 (D). The dotted line lines indicate the cut-off for positivity used in each assay, as calculated by ROC analysis. The percent fraction of Ab+ sera is indicated on top of each distribution, while bars indicate the corresponding median±interquartile range. AUC and <i>p</i> values are given in the top right corner. Figure shows representative experiments out of three performed.</p

Correlation between titers of RSR ZnT8 Ab and MAP reactive Abs.

<p>Correlation is shown between titers of Abs recognizing (A) ZnT8RSR Abs and MAP3865c_281–287 C-terminal epitope; (B) ZnT8RSR Abs and MptD MAP specific protein. Each circle represents the titer of one T1D child. The dotted line lines indicate the cut-off for positivity used in each assay, as calculated by ROC analysis.</p

Prevalence of Abs against homologous MAP3865c and ZnT8 epitopes in T2D patients.

<p>Prevalence of Abs against MAP3865c_125–133 (A) and its homologous ZnT8_178–186 (B); and against MAP3865c_133–141 (C) and its homologous ZnT8_186–194 (D) in T2D and healthy subjects. Data representation is the same as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026931#pone-0026931-g001" target="_blank">Fig. 1</a>.</p

Prevalence of Abs against homologous MAP3865c and ZnT8 epitopes in T1D patients.

<p>Prevalence of Abs against MAP3865c_125–133 (A) and its homologous ZnT8_178–186 (B); and against MAP3865c_133–141 (C) and its homologous ZnT8_186–194 (D) in T1D and healthy subjects. Data representation is the same as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026931#pone-0026931-g001" target="_blank">Fig. 1</a>.</p

(in the rats)

ratsWithdraw? APR 1980 [check]I suppose some sort of extension of DT's?Not usedNot usedWithdraw

Ab reactivities against the MAP3865c protein are inhibited by MAP3865c_125–133 and MAP3865c_133–141 peptides.

<p>Ab+ and Ab-negative sera from T1D patients were pre-incubated overnight with saturating concentrations (5.5 µM) of MAP3865c_125–133, MAP3865c_133–141, the two peptides in combination, MAP3865c-MBP fusion protein and control or no peptide. Their reactivity on MAP3865c-MBP-coated ELISA plates was subsequently tested. Bars depict means ± SEM of triplicate wells and results are representative of three separate experiments.</p

Prevalence of anti-MAP3865c Abs in Sardinian T1D and T2D patients.

<p>Sera were tested for their reactivity against plate-coated MAP3865c-MBP fusion protein. Ab distribution is shown for T1D (A) and T2D (B) patients compared to healthy controls. Dotted lines indicate the cut-off for positivity used in each assay, as calculated by ROC analysis. The percent fraction of Ab+ sera is indicated on top of each distribution, while bars indicate the corresponding median ± interquartile range. AUC and <i>p</i> values are given in the top right corner. Figures show representative experiments out of three performed.</p